Guardian

Demand for weight loss drugs is becoming unsustainable, say pharmacists

National Pharmacy Association

Pharmacies Warn Of Unsustainable Demand For Weight Loss Medication

Medscape

Weight Loss Drug Demand Risks Overwhelming Pharmacies

The Times

NHS struggling to cope with overwhelming weight-loss drug demand

Ozempic's popularity leads to shortages for people with Type 2 diabetes

Obesity Health Alliance

New Position Statement: A Way Forward for the Treatment of Obesity

<h2></h2>

Polling commissioned by the National Pharmacy Association (NPA), a nonprofit that represents independent pharmacies throughout the U.K., found that unprecedented demand for weight-loss medication could exceed supply in the near future.

Polling commissioned by the National Pharmacy Association (NPA), a nonprofit that represents independent pharmacies throughout the U.K., found that unprecedented demand for weight-loss medication could exceed supply in the near future.

In terms of demand, 41% of those polled said they would access weight-loss drugs if they were available through the National Health Service (NHS), with 64% of those 25-34 years old saying the same — despite many not being eligible to receive the drug.

In terms of demand, 41% of those polled said they would access weight-loss drugs if they were available through the National Health Service (NHS), with 64% of those 25-34 years old saying the same — despite many not being eligible to receive the drug.

In a statement, NPA chair Olivier Picard said that the increased demand "highlights the need to make sure" the drugs are "appropriate for those who want it" in the face of a potential shortage. Picard said it's important to "carefully manage" supplies so those who need the drugs most can access them.

In a statement, NPA chair Olivier Picard said that the increased demand "highlights the need to make sure" the drugs are "appropriate for those who want it" in the face of a potential shortage. Picard said it's important to "carefully manage" supplies so those who need the drugs most can access them.

This April, 1.6 million packs of Mounjaro and Wegovy, which are licensed for patients with a BMI over 30 or between 27 and 30 with at least one weight-related comorbidity, were purchased in the U.K.

This April, 1.6 million packs of Mounjaro and Wegovy, which are licensed for patients with a BMI over 30 or between 27 and 30 with at least one weight-related comorbidity, were purchased in the U.K.

This comes after U.K. Prime Minister Keir Starmer, during the launch of the 10-Year Health Plan, promised "innovative weight loss services" through pharmacies would be made available. But no details on this plan have been forthcoming.

This comes after U.K. Prime Minister Keir Starmer, during the launch of the 10-Year Health Plan, promised "innovative weight loss services" through pharmacies would be made available. But no details on this plan have been forthcoming.

The Obesity Health Alliance (OHA) previously urged the NHS to reform services because "unprecedented" demand for weight-loss drugs was putting "immense pressure" on health service providers.

The Obesity Health Alliance (OHA) previously urged the NHS to reform services because "unprecedented" demand for weight-loss drugs was putting "immense pressure" on health service providers.

Guardian #3084

National Pharmacy Association #

Medscape #

The Times #

NPR #5345

Obesity Health Alliance #

Polling commissioned by the National Pharmacy Association (NPA), a non-profit that represents independent pharmacies throughout the UK, found that unprecedented demand for weight-loss medication could exceed supply in the near future.

Polling commissioned by the National Pharmacy Association (NPA), a non-profit that represents independent pharmacies throughout the UK, found that unprecedented demand for weight-loss medication could exceed supply in the near future.

This April, 1.6 million packs of Mounjaro and Wegovy, which are licensed for patients with a BMI over 30 or between 27 and 30 with at least one weight-related co-morbidity, were purchased in Britain.

This April, 1.6 million packs of Mounjaro and Wegovy, which are licensed for patients with a BMI over 30 or between 27 and 30 with at least one weight-related co-morbidity, were purchased in Britain.

This comes after UK Prime Minister Kier Starmer, during the launch of the 10-Year Health Plan, promised "innovative weight-loss services" through pharmacies would be made available. But no details on this plan have been forthcoming.

This comes after UK Prime Minister Kier Starmer, during the launch of the 10-Year Health Plan, promised "innovative weight-loss services" through pharmacies would be made available. But no details on this plan have been forthcoming.

Also, the Obesity Health Alliance (OHA) previously urged the NHS to reform services because "unprecedented" demand for weight-loss drugs was putting "immense pressure" on health service providers.

Also, the Obesity Health Alliance (OHA) previously urged the NHS to reform services because "unprecedented" demand for weight-loss drugs was putting "immense pressure" on health service providers.

The government has to step up to take the burden off of health providers. Too many people dealing with obesity aren't receiving the necessary level of government support to manage their condition, and they're turning to these drugs, which aren't widely available. It's time for these people to receive more support.

The government has to step up to take the burden off of health providers. Too many people dealing with obesity aren't receiving the necessary level of government support to manage their condition, and they're turning to these drugs, which aren't widely available. It's time for these people to receive more support.

The health agencies have done their job creating strict guidelines, but the drug companies who advertise these medicines as beneficial for people of all types are causing the rise in demand. They also should've been more prepared for the drugs' success and the demand that would follow. No one who doesn't needed these druing should get them.

The health agencies have done their job creating strict guidelines, but the drug companies who advertise these medicines as beneficial for people of all types are causing the rise in demand. They also should've been more prepared for the drugs' success and the demand that would follow. No one who doesn't needed these druing should get them.

Dhiraj Singh/Bloomberg via Getty Images

Poll: Weight-Loss Drug Demand Could Outstrip Supply

Dhiraj Singh/Bloomberg via Getty Images

Poll: Weight-Loss Drug Demand Could Outstrip Supply

Healthcare

United States of America

Health agencies have done their job creating strict guidelines, but the drug companies that advertise these medicines as beneficial for people of all types are causing the rise in demand. They also should've been more prepared for the drugs' success and the demand that would follow. No one who doesn't need these drugs should get them.

Health agencies have done their job creating strict guidelines, but the drug companies that advertise these medicines as beneficial for people of all types are causing the rise in demand. They also should've been more prepared for the drugs' success and the demand that would follow. No one who doesn't need these drugs should get them.

There's an 80.8% chance that oral semaglutide will be be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

There's an 80.8% chance that oral semaglutide will be be approved for the treatment of obesity by the FDA or EMA by 2027, according to the Metaculus prediction community.

Poll: Weight-Loss Drug Demand Could Outstrip Supply

Poll: Weight-Loss Drug Demand Could Outstrip Supply

The Spin

Metaculus Prediction

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Poll: Weight-Loss Drug Demand Could Outstrip Supply

Poll: Weight-Loss Drug Demand Could Outstrip Supply

The Spin

Metaculus Prediction

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters